The Zhitong Finance App learned that Liankang Biotechnology Group (00690) rose nearly 9%. As of press release, it had risen 8.7% to HK$0.1, with a turnover of HK$2,067,300.
According to the news, Liankang Biotechnology Group announced yesterday that the National Drug Administration (NMPA) approved the marketing application for Bogutai (teriparatide injection) independently developed by the group on January 16, 2024. According to reports, Boghutai (teriparatide injection) is the fifth product launched by the Group after Jinyin Peptide, Jin Yinshu, and Pina popularized Boshutai. It is also the first disposable pre-filled pen-style teriparatide injection made in China.